



## Management Change

**Brisbane 25<sup>th</sup> January 2019:** Factor Therapeutics (ASX:FTT, the “Company”) announces that Dr Rosalind Wilson has completed her tenure as Chief Executive Officer and been retained, on a part-time consulting basis, to assist with progressing the Company’s future plans.

Dr Wilson joined Factor Therapeutics in mid-2017, overseeing completion of the Phase 2 clinical programme in venous leg ulcer healing and the limited expansion of the Company’s pipeline.

Since the Phase 2 results Dr Wilson has been working with the team and Board to ensure an orderly completion of the Company’s previous research and development activities. This process is almost complete and the Board is now actively evaluating several opportunities to take the Company forward.

“On behalf of the Board, I would like to thank Ros for her contribution and commitment to the Company during her time as CEO. Moving forward, we are pleased to be able to call on her experience and corporate knowledge as we formulate plans for the future, with a clear focus on doing all we can to achieve the best available outcome for our shareholders,” said Dr Cherrell Hirst, Chairman of Factor Therapeutics.

**-ENDS-**

### **Contact for Further Information:**

Dr. Rosalind Wilson  
Chief Executive Officer  
Factor Therapeutics Limited  
[r.wilson@factor-therapeutics.com](mailto:r.wilson@factor-therapeutics.com)

### **About Factor Therapeutics**

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>